Catherine Mackey

Catherine J.
Mackey currently works at Cyprus Therapeutics, Inc., as Chief Executive Officer from 2015, Rady Children's Health, as Director from 2006, San Diego Athena, as Director-Emeritus, Voyager Therapeutics, Inc., as Independent Director from 2022, and IDEAYA Biosciences, Inc., as Independent Director from 2022.
Dr. Mackey also formerly worked at Cour Pharmaceuticals Development Co., Inc., as Chairman from 2014 to 2022, Sequenom, Inc., as Director from 2015 to 2016, YM BioSciences, Inc., as Independent Director from 2012 to 2013, Viventia Biotech, Inc., as Director, Genelux Corp., as Director, Trillium Therapeutics, Inc., as Director in 2021, GW Pharmaceuticals Ltd., as Independent Non-Executive Director from 2017 to 2021, Ajinomoto Althea, Inc., as Director, CONNECT, as Director, Viventia Bio, Inc., as Director from 2015 to 2016, Poseida Therapeutics, Inc., as Independent Director from 2019 to 2021, Avid Bioservices, Inc., as Independent Director from 2019 to 2025, Biocom, Inc., as Director, Project Concern International, as Director from 2007 to 2024, Infinant Health, Inc., as Director from 2014 to 2017, Rady Children's Institute for Genomic Medicine, as Director from 2015 to 2024, DEKALB Genetics Corp., as Vice President from 1990 to 1998, and Pfizer Inc., as Senior VP-Worldwide Research & Development from 2001 to 2010.
Dr. Mackey received her undergraduate degree in 1977 from Cornell University and doctorate degree in 1983 from Cornell University.